XML 72 R55.htm IDEA: XBRL DOCUMENT v3.24.2

Note 21 - Non-controlling Interests (Tables)

12 Months Ended

May 31, 2024

Notes Tables

Condensed Balance Sheet [Table Text Block]

		SH				CC Pharma				Aphria				ColCanna				May 31,
		Acquisition				Nordic ApS				Diamond				S.A.S.				2024
Current assets		$	—			$	12			$	95,720			$	3			$	95,735
Non-current assets			32,000				—				124,675				3,637				160,312
Current liabilities			—				(9	)			(130,945	)			(6,913	)			(137,867	)
Non-current liabilities			—				—				(24,482	)			(1,452	)			(25,934	)
Net assets		$	32,000			$	3			$	64,968			$	(4,725	)		$	92,246

		SH				CC Pharma				Aphria				ColCanna				May 31,
		Acquisition				Nordic ApS				Diamond				S.A.S.				2023
Current assets		$	—			$	114			$	127,689			$	224			$	128,027
Non-current assets			74,681				—				135,085				3,307				213,073
Current liabilities			—				(1,166	)			(142,554	)			(6,697	)			(150,417	)
Non-current liabilities			—				—				(53,197	)			(1,428	)			(54,625	)
Net assets		$	74,681			$	(1,052	)		$	67,023			$	(4,594	)		$	136,058

Condensed Income Statement [Table Text Block]

		SH				CC Pharma				Aphria				ColCanna				May 31,
		Acquisition				Nordic ApS				Diamond				S.A.S.				2024
Revenue		$	—			$	—			$	103,331			$	—			$	103,331
Total expenses			42,681				(1,064	)			40,935				(203	)			82,349
Net (loss) income			(42,681	)			1,064				62,396				203				20,982
Other comprehensive (loss) income			—				(9	)			171				(334	)			(172	)
Net comprehensive (loss) income		$	(42,681	)		$	1,055			$	62,567			$	(131	)		$	20,810
Non-controlling interest %			32	%			25	%			49	%			10	%		NA
Comprehensive (loss) income attributable to NCI			(13,658	)			264				30,658				(13	)			17,251
Additional income attributable to NCI			—				—				5,336				—				5,336
Net comprehensive (loss) income attributable to NCI		$	(13,658	)		$	264			$	35,994			$	(13	)		$	22,587

		SH				CC Pharma				Aphria				ColCanna				May 31,
		Acquisition				Nordic ApS				Diamond				S.A.S.				2023
Revenue		$	—			$	126			$	161,453			$	1			$	161,580
Total expenses			107,297				748				85,460				57,293				250,798
Net (loss) income			(107,297	)			(622	)			75,993				(57,292	)			(89,218	)
Other comprehensive (loss) income			70,778				(21	)			(961	)			(34,643	)			35,153
Net comprehensive (loss) income		$	(36,519	)		$	(643	)		$	75,032			$	(91,935	)		$	(54,065	)
Non-controlling interest %			32	%			25	%			49	%			10	%		NA
Comprehensive (loss) income attributable to NCI			(11,686	)			(161	)			36,766				(9,194	)			15,725
Additional income attributable to NCI			—				—				11,421				—				11,421
Net comprehensive (loss) income attributable to NCI		$	(11,686	)		$	(161	)		$	48,187			$	(9,194	)		$	27,146

		SH				CC Pharma				Aphria				ColCanna				May 31,
		Acquisition				Nordic ApS				Diamond				S.A.S.				2022
Revenue		$	—			$	354			$	148,323			$	—			$	148,677
Total expenses (recovery)			(11,180	)			470				77,057				35				66,382
Net (loss) income			11,180				(116	)			71,266				(35	)			82,295
Other comprehensive (loss) income			(70,778	)			47				(2,353	)			(4,737	)			(77,821	)
Net comprehensive (loss) income		$	(59,598	)		$	(69	)		$	68,913			$	(4,772	)		$	4,474
Non-controlling interest %			32	%			25	%			49	%			10	%		NA
Net comprehensive (loss) income		$	(19,071	)		$	(17	)		$	33,767			$	(477	)		$	14,202

X

- Definition

Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 04
-Paragraph a
-Publisher SEC

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix:	srt_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 04
-Paragraph a
-Publisher SEC

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix:	srt_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration